Analysis of the quality of anticoagulation with vitamin K antagonists in three clinical scenarios in Mexico.

Introduction: Vitamin K antagonists (VKA) are a therapeutic alternative in patients with venous thromboembolic disease; however, numerous factors affect their pharmacology.

Objective: To evaluate the quality of VKA anticoagulation at three different time periods in Mexico.

Methods: Prospective study, nested in patient cohorts at three different clinical scenarios between 2013 and 2019.

A proposal for the management of COVID-19-induced coagulopathy in adults.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the cause of the coronavirus disease 2019 (COVID-19) pandemic, which has a high case fatality rate. Most severely ill patients develop a special type of coagulopathy that had not been described before and that is now considered the main cause of death. For this reason, anticoagulant treatment has become one of the cornerstones of the treatment of this infection.